Journal: Infection Prevention in Practice

Article Title: Prevalence of side‐effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia

doi: 10.1016/j.infpip.2022.100251

Figure Lengend Snippet: Total number of COVID‐19 vaccine side‐effects reported among the participants associated with COVID-19 Booster dose-vaccine of Pfizer-BioNTech (BNT162b2) among respondents.

Article Snippet: Total number of COVID‐19 vaccine side‐effects reported among the participants associated with COVID-19 Booster dose-vaccine of Pfizer-BioNTech (BNT162b2) among respondents.

Techniques:

Journal: Infection Prevention in Practice

Article Title: Prevalence of side‐effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia

doi: 10.1016/j.infpip.2022.100251

Figure Lengend Snippet: Frequency and types of side‐effects associated with COVID-19 Vaccines among respondents.

Article Snippet: Total number of COVID‐19 vaccine side‐effects reported among the participants associated with COVID-19 Booster dose-vaccine of Pfizer-BioNTech (BNT162b2) among respondents.

Techniques:

Journal: medRxiv

Article Title: Variability in mRNA SARS-CoV-2 BNT162b2 vaccine immunogenicity is associated with differences in the gut microbiome and habitual dietary fibre intake

doi: 10.1101/2022.08.24.22279143

Figure Lengend Snippet: Change in specific taxonomy and SCFA production from baseline to twelve-weeks post 1 st BTN162b2 vaccine. (A) A significant reduction in Actinobacteriota (p<0.0001), Anaerostipes (p=0.00161) and Blautia (p=0.00103) an increase in Lachnoclostridium (p=0.00179) were observed after the 1 st BNT162b2 vaccine. (B) No significant changes (p>0.05) in SCFAs were observed after the 1 st BNT162b2 vaccine. P-values determined using Wald test of significance.

Article Snippet: Uninfected healthcare workers aged ≥ 18 years were prospectively recruited at British Columbia Children’s Hospital (Vancouver, Canada) between February and August 2021 prior to receiving two Pfizer-BioNtech BNT162b2 mRNA vaccine doses, approximately 4 months apart.

Techniques:

Journal: medRxiv

Article Title: Variability in mRNA SARS-CoV-2 BNT162b2 vaccine immunogenicity is associated with differences in the gut microbiome and habitual dietary fibre intake

doi: 10.1101/2022.08.24.22279143

Figure Lengend Snippet: Correlation between baseline gut microbiota taxa and immune parameters twelve-weeks post 1 st BNT162b2 vaccine. (A) The variability in RBD and spike IgG, competitive binding antibody and IgG to competitive binding antibody ratio explained by the variability in gut microbiota composition (PERMANOVA). (B) Heat-map of the gut microbiota taxa positively (red) or negatively (blue) correlated with each of the immune parameters (*p<0.05; Wald test). (C) Baseline Prevotella counts were positively associated with RBD IgG levels post 1 st BNT162b2 vaccine (p=0.032; Wald test). (D) Baseline Clostridiales bacterium DTU089 and CAG-352, and Megasphaera counts were negatively associated with RBD competitive binding antibody levels post 1 st BNT162b2 vaccine (p=0.038, p=0.038 and p=0.047, respectively; Wald test). (E) Baseline Clostridiales bacterium DTU089 counts were negatively associated with spike competitive binding antibody levels post 1 st BNT162b2 vaccine (p=0.029; Wald test).

Article Snippet: Uninfected healthcare workers aged ≥ 18 years were prospectively recruited at British Columbia Children’s Hospital (Vancouver, Canada) between February and August 2021 prior to receiving two Pfizer-BioNtech BNT162b2 mRNA vaccine doses, approximately 4 months apart.

Techniques: Binding Assay

Journal: medRxiv

Article Title: Variability in mRNA SARS-CoV-2 BNT162b2 vaccine immunogenicity is associated with differences in the gut microbiome and habitual dietary fibre intake

doi: 10.1101/2022.08.24.22279143

Figure Lengend Snippet: Correlation between baseline SCFA and immune parameters twelve-weeks post 1 st BNT162b2 vaccine. (A) Heat-map of the specific SCFAs that were negatively (blue) or positively (yellow) correlated with each of the immune response parameters (*p<0.05; Spearman rank). (B) Baseline isovaleric acid concentrations were negatively associated with RBD IgG levels (p=0.0303, r= -0.373; Spearman rank). (C) Baseline isobutyric and isovaleric acid concentrations were negatively associated with spike IgG to competitive binding antibody ratio levels (p=0.0179, r= -0.406 and p=0.033, r= -0.367, respectively; Spearman rank). (D) Baseline isovaleric acid concentrations were negatively associated with spike IgG levels (p=0.0265, r= -0.381; Spearman rank).

Article Snippet: Uninfected healthcare workers aged ≥ 18 years were prospectively recruited at British Columbia Children’s Hospital (Vancouver, Canada) between February and August 2021 prior to receiving two Pfizer-BioNtech BNT162b2 mRNA vaccine doses, approximately 4 months apart.

Techniques: Binding Assay

Journal: medRxiv

Article Title: Variability in mRNA SARS-CoV-2 BNT162b2 vaccine immunogenicity is associated with differences in the gut microbiome and habitual dietary fibre intake

doi: 10.1101/2022.08.24.22279143

Figure Lengend Snippet: Significant differences in baseline microbial taxa in participants with differential (lowest [quartile 1] versus highest [quartile 4]) immune parameter responses twelve-weeks post 1 st BNT162b2 vaccine. (A) A trend towards a significant difference (p=0.0554; PERMANOVA) in the gut microbiota community was observed in participants with the lowest (quartile 1 [pink]) versus the highest (quartile 4 [green]) RBD IgG response twelve-weeks post 1 st BNT162b2 vaccine dose. (B) Heat-map depicting several significantly higher (red) or lower (blue) (*p<0.05; Wald test) baseline microbial counts in high (quartile 4) versus low (quartile 1) BTN162b2 vaccine responders across several immune parameters. (C) Baseline Prevotella and Haemophilus counts were significantly (p=0.00016 and p<0.0001, respectively; Wald test) higher in participants with the highest (quartile 4) RBD IgG levels twelve-weeks post 1 st BNT162b2 vaccine. (D) Baseline Prevotella and Haemophilus counts were significantly (p=0.00029 and p=0.00049, respectively; Wald test) higher in participants with the highest (quartile 4) ratio of RBD IgG to competitive binding antibody levels twelve-weeks post 1 st BNT162b2 vaccine. (E) Baseline Haemophilus and Veillonella counts were significantly (p=0.0043 and p<0.0001, respectively; Wald test) higher in participants with the highest (quartile 4) RBD competitive binding antibody levels twelve-weeks post 1 st BNT162b2 vaccine. (F) Baseline Prevotella counts were significantly (p=0.00544; Wald test) higher in participants with the highest (quartile 4) ratio of RBD IgG to competitive binding antibody twelve-weeks post 1 st BNT162b2 vaccine. (G) Individuals with the highest baseline concentrations (μmol/g stool) of isobutyric acid had the lowest spike IgG to competitive binding antibody ratio levels (p=0.045; t-test, Bonferroni corrected) while those with the highest baseline concentrations of isovaleric acid had the lowest RBD competitive binding antibody, RBD IgG and spike IgG levels (p=0.021, p=0.044 and p=0.042, respectively; t-test, Bonferroni corrected).

Article Snippet: Uninfected healthcare workers aged ≥ 18 years were prospectively recruited at British Columbia Children’s Hospital (Vancouver, Canada) between February and August 2021 prior to receiving two Pfizer-BioNtech BNT162b2 mRNA vaccine doses, approximately 4 months apart.

Techniques: Binding Assay

Journal: medRxiv

Article Title: Variability in mRNA SARS-CoV-2 BNT162b2 vaccine immunogenicity is associated with differences in the gut microbiome and habitual dietary fibre intake

doi: 10.1101/2022.08.24.22279143

Figure Lengend Snippet: Significant associations between certain microbial species and total relative fractional avidity (TRFA). Several gut microbiota species were significantly positively or negatively associated (p<0.01; Wald test) with higher avidity after the 1 st dose of the BNT162b2 vaccine (V2) in a subset of participants (n=15). Several gut microbiota species were also significantly positively or negatively associated (p<0.01; Wald test) with higher avidity after the 2 nd dose of the BNT162b2 vaccine (V3) in a subset of participants (n=15). Refer to table 3 and 4 for the specific species names and p values.

Article Snippet: Uninfected healthcare workers aged ≥ 18 years were prospectively recruited at British Columbia Children’s Hospital (Vancouver, Canada) between February and August 2021 prior to receiving two Pfizer-BioNtech BNT162b2 mRNA vaccine doses, approximately 4 months apart.

Techniques:

Journal: medRxiv

Article Title: Variability in mRNA SARS-CoV-2 BNT162b2 vaccine immunogenicity is associated with differences in the gut microbiome and habitual dietary fibre intake

doi: 10.1101/2022.08.24.22279143

Figure Lengend Snippet: Differences in the gut microbiota community between low, moderate, and high habitual dietary fibre consumers at baseline and twelve-weeks post 1 st dose of the BNT162b2 vaccine. (A) At baseline, differing habitual dietary fibre intakes led to a trend towards significant differences (p=0.061; PERMANOVA) in the structure of the gut microbiota community. Twelve-weeks post 1 st dose of the BNT162b2 vaccine differing habitual dietary fibre intakes led to a trend towards significant differences (p=0.0558; PERMANOVA) in the structure of the gut microbiota community. (B) A significant shift in the gut microbiota was revealed in low (p=0.0332; PERMANOVA) but not moderate and high dietary fibre consumers (p=0.511 and p=0.517, respectively; PERMANOVA) twelve-weeks after the 1 st dose of the BNT162b2 vaccine. (C) After the 1 st dose of the BNT162b2 vaccine TRFA was lower in high dietary fibre consumers but not significantly (p=0.058; Kruskal-Wallis). (D) High dietary fibre consumers had a significantly (p=0.018; Kruskal-Wallis) greater change in TRFA from the 1 st to 2 nd BNT162b2 dose compared to low and moderate dietary fibre consumers.

Article Snippet: Uninfected healthcare workers aged ≥ 18 years were prospectively recruited at British Columbia Children’s Hospital (Vancouver, Canada) between February and August 2021 prior to receiving two Pfizer-BioNtech BNT162b2 mRNA vaccine doses, approximately 4 months apart.

Techniques:

Journal: Scientific Reports

Article Title: Ultrasensitive detection of salivary SARS-CoV-2 IgG antibodies in individuals with natural and COVID-19 vaccine-induced immunity

doi: 10.1038/s41598-022-12869-z

Figure Lengend Snippet: Distribution of SARS-CoV-2 spike protein RBD total antibody AI values using a home-brew ELISA in pre- and post-COVID-19 vaccination serum and saliva samples. Serum and saliva were obtained from 40 individuals prior to and after COVID-19 vaccination. Antibody indices were measured using a laboratory-developed SARS-CoV-2 total antibody ELISA. The positive antibody index cut-off for serum samples was 4.0 and 2.8 for saliva samples. ( a ) Changes in AI pre- and post-vaccination in serum and saliva in the context of the positive cut-off value for each sample type. ( b ) Pre- vs. post-vaccination AI ratios in serum and saliva.

Article Snippet: Paired serum and saliva specimens were obtained from a cohort of 40 donors at the University of Minnesota prior to and 2 weeks after receiving an initial COVID-19 vaccine dose (Pfizer/BioNTech BNT162b2 or Moderna mRNA-1273) [Age range: 18–65; 40% male, 60% female].

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Scientific Reports

Article Title: Ultrasensitive detection of salivary SARS-CoV-2 IgG antibodies in individuals with natural and COVID-19 vaccine-induced immunity

doi: 10.1038/s41598-022-12869-z

Figure Lengend Snippet: Concordance of SARS-CoV-2 spike protein RBD AI values among serum and saliva samples from individuals with natural and vaccine-induced COVID-19 immunity using the home-brew ELISA. SARS-CoV-2 RBD total antibody levels were measured in serum and SARS-CoV-2 RBD IgG antibody levels were measured in concentrated saliva samples using a laboratory-developed ELISA. ( a ) Total RBD antibody levels in serum and RBD IgG antibody levels in saliva samples from convalescent plasma donors (n = 26) with natural COVID-19 immunity and individuals with vaccine-induced COVID-19 immunity (n = 40). ( b ) RBD IgG antibody levels in saliva and serum from convalescent plasma donors (n = 26) with natural COVID-19 immunity. AI antibody index.

Article Snippet: Paired serum and saliva specimens were obtained from a cohort of 40 donors at the University of Minnesota prior to and 2 weeks after receiving an initial COVID-19 vaccine dose (Pfizer/BioNTech BNT162b2 or Moderna mRNA-1273) [Age range: 18–65; 40% male, 60% female].

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Scientific Reports

Article Title: Ultrasensitive detection of salivary SARS-CoV-2 IgG antibodies in individuals with natural and COVID-19 vaccine-induced immunity

doi: 10.1038/s41598-022-12869-z

Figure Lengend Snippet: Distribution of SARS-CoV-2 spike protein RBD IgG antibody levels in pre- and post-COVID-19 vaccination unconcentrated saliva samples measured using a Simoa immunoassay with and without total IgG normalization. The levels of SARS-CoV-2 RBD IgG were measured in the saliva from 36 pre-vaccinated individuals and 34 post-vaccinated individuals. The positive cut-off was 153 pg/mL. ( a ) Direct (non-normalized) values. ( b ) RBD IgG values (in ng/mL) normalized to total IgG levels (in ng/mL) and multiplied by 1000.

Article Snippet: Paired serum and saliva specimens were obtained from a cohort of 40 donors at the University of Minnesota prior to and 2 weeks after receiving an initial COVID-19 vaccine dose (Pfizer/BioNTech BNT162b2 or Moderna mRNA-1273) [Age range: 18–65; 40% male, 60% female].

Techniques: